Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Limetree Publishing

An independent, custom medical publisher providing educational content across all formats. It is our commitment to present well-balanced content with real, practical value to HCPs and patients.

This is a FREE LISTING on PMHUB

Below are full profiles from other companies in related areas

Springer Nature

Springer Nature

Did you know that we publish over 3,000 journals, and that over 1,000 of those are clinical science journals? Promote your approved branded drugs and medical devices to our audience…

View Profile

Advertising, Medical communications, Publishers

Streaming Well - Video For Healthcare

Streaming Well

Streaming Well is a healthcare-focused, award-winning video production company which operates in the US and Europe. We create engaging visual stories and interactive experiences that connect with people.

View Profile

Advertising, Branding, Clinical Research, Conference/meetings/events, Creative and design, Digital communications, Medical communications, Medical education, Publishers, Translation services

- PMLiVE

Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that we attend each year.

View Profile

Medical communications, Medical education, Publishers

Company Details

Limetree Publishing
The Limes, Worlingworth Road, Horham, Suffolk, IP21 5ER, UK
01379 388932
Contact Limetree Publishing
Website

 Latest Content from PMHub 

It’s Teenage Kicks for Lucid Group

Press Releases | February 14, 2020 | Lucid Group Communications Limited

Lucid has been celebrating its 13th birthday this week. From New York to Singapore, Dubai, Macclesfield and London, teams have been gathering to celebrate the start of its teenage years.The...

Love – it really does make the world go around

White Papers and Resources | February 12, 2020 | Page & Page Health

No two people are the same nor as individuals are we particularly predictable – we might like to think we are because at some point in time someone decided that...

OPEN Health supports Genetic Alliance UK’s Rare Film Festival!

White Papers and Resources | February 12, 2020 | OPEN Health

OPEN Health joined a number of rare disease patients, patient groups and industry representatives at the Regent Street cinema in London to see the winners announced at the Rare Film...

This isn’t goodbye, it’s see you in August!

Press Releases | February 12, 2020 | Resonant Group

Bedrock Group imagines, creates and delivers industry-leading benefits

Courageous Conversations ep.2: What Our Healthcare System Can Learn from AlphaGo

Videos and Podcasts | February 11, 2020 | Impetus Digital

Courageous Conversations ep.1: Why Our Healthcare System is in Dire Need of Disruption

Videos and Podcasts | February 11, 2020 | Impetus Digital

Onyx Health receive national recognition as a “one to watch” business in Newcastle

Press Releases | February 10, 2020 | Onyx Health

Specialist marketing communications agency Onyx Health have been nationally recognised by The Sunday Times as one of six “one to watch” businesses based in Newcastle.

What is adult learning theory and how can it be used to help maximise your team’s potential?

White Papers and Resources | February 10, 2020 | OPEN Health

Written by Briony Frost, OPEN Health

Lighthouse Medical Communications US – An opportunity of a lifetime to be part of the Lucid Group magic

Videos and Podcasts | February 6, 2020 | Lucid Group Communications Limited

Our family at Lighthouse Medical Communications US are looking for talented individuals to join its team in hashtagManhattan. If you want to be part of something magical get in touch...

Blueberry Therapeutics receives clearance from the FDA to proceed with the clinical investigation of BB2603

Press Releases | February 3, 2020 | Onyx Health

Blueberry Therapeutics has received an investigational new drug (IND) clearance from the Food and Drug Administration (FDA) to proceed with the clinical development of BB2603